Zealand Pharma seeks development partner for promising diabetes drug  

Type 2 diabetes drug ZP10 shows promising results in clinical studies in humans

Copenhagen-based Zealand Pharma has announced promising results from a study with its Type 2 diabetes drug ZP10, which acts on the so-called Glucagon-like Peptide-1 (GLP-1) receptor and stops the development of diabetes at an early stage before insulin is needed. No safety issues were identified during the placebo controlled study and a near-maximum effect was seen at a dose level at which no side effects were observed. ZP10 was also demonstrated to increase insulin secretion. Zealand Pharma is now seeking a partner in the traditional pharmaceutical industry to further develop and market the drug.


Zealand Pharma is a biopharmaceutical company focusing on discovery and development of innovative drugs which significantly improve existing treatment. The focus of its R&D is intercellular communication and modification of peptides. The company was established in 1998 and currently employs 40 people.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×